Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

BACKGROUND. Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Armstrong, Andrew J., Humeniuk, Michael S., Healy, Patrick, Szmulewitz, Russell, Winters, Carolyn, Kephart, Julie, Harrison, Michael R., Martinez, Elia, Mundy, Kelly, Halabi, Susan, George, Daniel
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6309626/
https://ncbi.nlm.nih.gov/pubmed/27862097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23277
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados